You can find information below regarding the current recruitment status for MND studies and clinical trials that are taking place across the UK.
If you have taken part in a study, you may be interested to find out more about the progress of the study or view the study results. Please be aware that some studies are global in scale and can take place over a long timeframe. Because of this, the results may not be published until some time after your participation has ended. Once studies have closed to recruitment, they move to this section of the website. We are working with researchers to encourage them to share the findings of their research studies as soon as they are available, and collating the information we receive on the Closed studies page here.
We aim to update the information on this page on a monthly basis.
| Study Title | Current UK recruitment (last updated 01Nov2021) / UK Recruitment target | Planned UK Recruitment End Date | Current Study Status | Study Website / Publications |
|---|---|---|---|---|
| AMBRoSIA | 760 / 585 (130% recruitment target achieved) | 14/12/2021 | Active, recruiting | AMBRoSIA |
| ALS Biomarkers Study | 1208 / 1500 (81% recruitment target achieved) | 31/12/2025 | Active, recruiting | ALS Biomarkers Study |
| ALSFRS-R Online Validation | 187 / 100 (187% recruitment target achieved) | 01/02/2021 | Active, recruiting | ALSFRS-R Online Validation Study |
| COMMEND RCT | 111 / 188 (59% recruitment target achieved) | 31/05/2022 | Active, recruiting | COMMEND randomised controlled trial |
| C9orf72 Cohort Study | 102 / 90 (113% recruitment target achieved) | 30/06/2022 | Active, recruiting | C9orf72 Cohort Study |
| DiAMoND Study: Phase 3 | 0 / 170 (0% recruitment target achieved) | 31/12/2021 | Active, recruiting | |
| Measuring Cognitive and Behavioural Change in ALS | 247 / 305 (81% recruitment target achieved) | 30/06/2021 | Active, recruiting | Measuring Cognitive and Behavioural Change in ALS |
| Apellis phase 2 Pegcetacoplan trial (MERIDIAN) | 0 / 15 (0% recruitment target achieved) | 01/08/2021 | Active, recruiting | |
| MIND-MAPS-ALS | 0 / 16 (0% recruitment target achieved) | 01/01/2023 | Active, recruiting | |
| MiNDToolkit Feasibility Study | 0 / 20 (0% recruitment target achieved) | 31/05/2022 | Active, recruiting | MiNDToolkit Feasibility Study |
| MND Register | 2696 / 950 (284% recruitment target achieved) | 31/12/2021 | Active, recruiting | MND Register |
| MND-SMART | 208 / 750 (28% recruitment target achieved) | 02/11/2026 | Active, recruiting | MND-SMART |
| Motor System Genomics | 1109 / 2000 (55% recruitment target achieved) | 30/09/2022 | Active, recruiting | Motor System Genomics |
| Neuro Digital: Outpatient Perspectives Study | 0 / 64 (0% recruitment target achieved) | 28/01/2022 | Active, recruiting | |
| Novel Electrical Impedance Spectroscopy for Neurological disorders | 56 / 175 (32% recruitment target achieved) | 31/03/2022 | Active, recruiting | Novel Electrical Impedance Spectroscopy |
| OptiCALS Randomised Controlled Trial | 13 / 334 (4% recruitment target achieved) | 02/11/2022 | Active, recruiting | |
| PostGas | 153 / 200 (77% recruitment target achieved) | 28/02/2022 | Active, recruiting | PostGas |
| Remote surface EMG in MND | 4 / 6 (67% recruitment target achieved) | 03/03/2022 | Active, recruiting | |
| RHAPSODY Speech-based biomarkers Pilot Study | 38 / 250 (15% recruitment target achieved) | 01/11/2021 | Active, recruiting | |
| Focus-C9 (Wave) phase 1 trial | 1 / 22 (5% recruitment target achieved) | 09/04/2023 | Active, recruiting | |
| TONiC | Phase 2: 12,203 / 11,700 (104% recruitment target achieved) Phase 3: 16,187 / 16,500 (98% recruitment target achieved) Phases 4 & 5: 3,446 / 1,500 (230% recruitment target achieved) | 30/11/2020 | Active, recruiting | Trajectories of Outcome in Neurological Conditions (TONiC) |
| TUDCA-ALS | 46 / 70 (66% recruitment target achieved) | 30/06/2021 | Active, recruiting | TUDCA-ALS trial |